Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Damora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get DMRA alerts

About Sherwin Sattarzadeh

Sherwin Sattarzadeh is recorded as CEO at Damora Therapeutics, Inc. (DMRA) since February 10, 2026 and COO at Damora Therapeutics, Inc. (DMRA). The newest filing on record that lists Sherwin Sattarzadeh as COO at Damora Therapeutics, Inc. (DMRA) is dated April 29, 2026. Damora Therapeutics, Inc. reported in an 8-K filed February 10, 2026 that Sherwin Sattarzadeh was appointed interim principal executive officer, effective February 10, 2026. Damora Therapeutics, Inc. reported in an 8-K filed January 6, 2026 that Sherwin Sattarzadeh was appointed Chief Operating Officer, effective January 5, 2026. Sherwin Sattarzadeh has spoken on 3 investor events across 1 company, most recently for Damora Therapeutics, Inc. on November 18, 2026. Damora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Damora Therapeutics, Inc. includes Jennifer Jarrett (CEO and Board Member), Peter Harwin (Chairman and Board Member), Lori Firmani (CFO) and 7 others.

“On February 6, 2026, the Board appointed Sherwin Sattarzadeh, the Company's current Chief Operating Officer, to serve as the Company's interim principal executive officer, effective as of the Effective Time.”
Damora Therapeutics, Inc. Form 8-K, filed February 10, 2026 · Read the filing
“On January 6, 2026, the Company announced that the board of directors (the “Board”) of the Company appointed Sherwin Sattarzadeh as the Company’s Chief Operating Officer, effective as of January 5, 2026 (the “Effective Date”).”
Damora Therapeutics, Inc. Form 8-K, filed January 6, 2026 · Read the filing

Sherwin Sattarzadeh on recent calls

“Yeah, so the first thing that we've learned is just the level of interest at the physician and patient level for therapies that are going to have this disease-modifying potential.”
COO, Jefferies Global Healthcare Conference ·
“Yeah, so it's a phase one, phase one B study that's open now in Australia and in the U.S. and will be, as Jen mentioned, opening the study in a number of other countries over the next few months.”
COO, UBS Global Biopharma Conference ·
“Before I get started, we're going to be making some forward-looking statements, so refer everyone to our latest SEC filings for risk factors and other information.”
COO, Guggenheim 3rd Annual Healthcare Innovation Conference ·

Affiliation history

Company network

Leadership on record at Damora Therapeutics, Inc.

Recent activity